Broad molecular profiling for targeted cancer care

Inivata’s proprietary technology is pioneering and draws on world-class research, based on original research conducted in the Rosenfeld lab at Cancer Research (CRUK), Cambridge and licensed from CRUK and University of Cambridge.

The InVision™ proprietary platform is a tagged-amplicon sequencing (TAm-Seq™) method, which allows amplification and deep sequencing of genomic regions spanning thousands of bases from individual copies of fragmented DNA.

InVision

Inivata’s proprietary technology is pioneering and draws on world-class research, based on original research conducted in the Rosenfeld lab at Cancer Research (CRUK), Cambridge and licensed from CRUK and University of Cambridge.

Plasma collection DNA extraction
ctDNA
analysis
Bioinformatics analysis
Oncology report generated

When analyzed with Inivata’s propriety algorithms and database, this can be used to generate a detailed report, providing critical insights into the patient’s tumor profile.

Stand-out sensitivity

InVision™ has been developed to provide an exceptional level of sensitivity, while retaining a comprehensive coverage.

>99% of mutations at >0.5% Allele Frequency